Liminatus Pharma, Inc. Warrants
NASDAQ Global SelectTotal Valuation
Liminatus Pharma, Inc. Warrants carries a market capitalization of 1.10M, placing it among publicly traded companies globally.
| Market Cap | 1.10M |
| Enterprise Value | N/A |
Share Statistics
Liminatus Pharma, Inc. Warrants currently has 44.88M shares outstanding.
| Shares Outstanding | 44.88M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Liminatus Pharma, Inc. Warrants maintains a current ratio of 0.96, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.96 |
| Quick Ratio | 0.66 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -47.30 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -796.77 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Liminatus Pharma, Inc. Warrants's stock has declined approximately -81.38587% over the past 52 weeks. The 50-day moving average sits at 0.06, while the 200-day moving average is 0.10.
| Beta (5Y) | N/A |
| 52-Week Price Change | -81.38587% |
| 50-Day Moving Average | 0.06 |
| 200-Day Moving Average | 0.10 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -2.68M, while operating income came in at -2.69M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -2.69M |
| Pretax Income | -11.12M |
| Net Income | -11.12M |
| EBITDA | -2.68M |
| EBIT | -2.69M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Total book value stands at -39.99M, with working capital of -110,877.00 providing operational flexibility.
| Cash & Cash Equivalents | 1.91M |
| Total Debt | N/A |
| Net Debt | -465,174.00 |
| Equity (Book Value) | -39.99M |
| Book Value Per Share | N/A |
| Working Capital | -110,877.00 |
Cash Flow
Liminatus Pharma, Inc. Warrants produced -11.82M in operating cash flow over the past twelve months.
| Operating Cash Flow | -11.82M |
| Capital Expenditures | N/A |
| Free Cash Flow | -11.82M |
| FCF Per Share | N/A |
Scores
Liminatus Pharma, Inc. Warrants posts an Altman Z-Score of -23.29, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -23.29 |